TETRYDAMINE MALEATE

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C9H15N3.C4H4O4
Molecular Weight	281.3077
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)\C=C/C(O)=O.CNC1=C2CCCCC2=NN1C

InChI

InChIKey=WBQNUTJPYOXRCC-BTJKTKAUSA-N

InChI=1S/C9H15N3.C4H4O4/c1-10-9-7-5-3-4-6-8(7)11-12(9)2;5-3(6)1-2-4(7)8/h10H,3-6H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1-

HIDE SMILES / InChI

Molecular Formula	C9H15N3
Molecular Weight	165.2355
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C4H4O4
Molecular Weight	116.0722
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1418890 | https://www.ncbi.nlm.nih.gov/pubmed/18608303 | http://en.pharmacodia.com/web/drug/1_9558.html | https://www.ncbi.nlm.nih.gov/pubmed/1881569

Tetrydamine is a member of the indazol class of non-steroidal anti-inflammatory drugs. It is an analgesic and anti-inflammatory drug. Tetrydamine lavage reduced or eliminated all inflammation symptoms like burning, leucorrhea, etc. and resulted very well tolerated in vulvovaginitis, symptomatic bacterial vaginosis and cervicitis treatment.

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Bacterial vaginosis 10 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1881569	Palliative	Approved 8583	Fomene Approved Use Unknown
Vulvovaginitis 5 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1418890	Palliative	Approved 8583	Fomene Approved Use Unknown
Cervicitis 3 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1418890	Palliative	Approved 8583	Fomene Approved Use Unknown

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252 inducer 1087	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2C19 2057 CYP1A2 2153 CYP19A1 429 P-gp 1741 BCRP 910	P-gp 2052

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1MDkxMTUifX0=	inconclusive [IC50 39.8107 uM]
BCRP 985	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/28446#section=BioAssay-Results Page: 34.0	no
CYP19A1 430	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/28446#section=BioAssay-Results Page: 203.0	no
CYP2C19 2141	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1MDkxMTUifX0=	no
CYP2C9 2497	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzk3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1MDkxMTUifX0=	no
CYP2D6 2546	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTUwOTExNSJ9fQ==	no
CYP3A4 2633	inducer 1966 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/28446#section=BioAssay-Results Page: 232.0	no
CYP3A4 2633	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTUwOTExNSJ9fQ==	no
MRP1 232	activator 342 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/28446#section=BioAssay-Results Page: 18.0	no
P-gp 1932	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/28446#section=BioAssay-Results Page: 34.0	no

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/28446#section=BioAssay-Results Page: 229 \| 232	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/28446#section=BioAssay-Results Page: 165.0

PubMed

Title	Date	PubMed
Oral tetridamine exposures.	2009-02	18608303
Activity and tolerability of tetridamine vaginal lavage in rats and women.	1992-03	1418890
[Tetridamine in the therapy of bacterial vaginosis].	1991-05	1881569
[Absorption, metabolism and excretion of 2-methyl-3-methylamino-4,5,6,7-tetrahydroindazole (tetridamine) in the rat].	1972-11	4655669

Patents

Sample Use Guides

In Vivo Use Guide

1 or 2 vaginal irrigations daily. The irrigation fluid is prepared by dissolving500 mg of the powder formulation in one liter of water.

Route of Administration: Vaginal

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 19:36:47 GMT 2025` Edited by `admin` on `Mon Mar 31 19:36:47 GMT 2025`
Record UNII	B976EB226W
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TETRYDAMINE MALEATE

Common Name

English

TETRIDAMINE MALEATE

Preferred Name

English

Tetridamine Maleate [WHO-DD]

Common Name

English

2H-INDAZOL-3-AMINE, 4,5,6,7-TETRAHYDRO-N,2-DIMETHYL-, (2Z)-2-BUTENEDIOATE (1:1)

Systematic Name

English

Code System Code Type Description

CAS

22911-97-3